VANDERBILT UNIVERSITY MEDICAL CENTER

Tulisokibart maintained clinical and endoscopic improvements in IBD patients through week 50 in phase II trial extensions, with 48% of ulcerative colitis patients and 56% of Crohn's disease patients achieving clinical remission. The drug was well-tolerated with no identified safety signals.

Women have historically been underrepresented in heart disease clinical trials, leading to inadequate understanding of sex-specific differences. Despite policy changes since the 1990s, women remain underrepresented in trials, particularly in heart failure with reduced ejection fraction (HFrEF) studies. Factors contributing to this include logistical barriers, lower awareness, and differing decision-making processes. Addressing these requires comprehensive strategies, including increased opportunities for women to participate, studying sex and gender interactions, and educating clinicians on women's heart disease.

P-BCMA-ALLO1, an allogeneic BCMA-directed T-cell therapy, showed high response rates in a phase 1/1b trial for relapsed/refractory multiple myeloma, with an overall response rate of 91% in the optimized lymphodepletion arm. The therapy received FDA's regenerative medicine advanced therapy designation in 2024.

Meiler lab awarded $46 million to develop a 'super-vaccine' against alphaviruses, leveraging computational techniques and a multidisciplinary team.

Vanderbilt Health Rx Solutions (VHRxS) launches a service to bridge the gap between specialty drug manufacturers and health systems, aiming to enhance patient care and optimize drug launches through pre- and post-launch strategies.

Vanderbilt Health Rx Solutions (VHRxS) launches a service to bridge gaps between specialty drug manufacturers and health systems, optimizing drug launches and enhancing patient care. The service, introduced by Cora Beth Enzor and Elizabeth Cherry at the National Association of Specialty Pharmacy, aims to break industry silos through collaborative partnerships and data-driven strategies.

P-BCMA-ALLO1, an allogeneic BCMA-targeted CAR T-cell therapy, showed high response rates in heavily pretreated patients with relapsed/refractory multiple myeloma, with an overall response rate of 91% in the optimized lymphodepletion arm (arm C). The therapy allows patients to skip invasive apheresis, bridging therapy, and manufacturing delays. The study, presented at the 21st International Myeloma Society Annual Meeting, also highlighted the therapy's safety profile, with no dose-limiting toxicities reported.

A study published in the American Journal of Respiratory and Critical Care Medicine on Aug. 1, 2024, developed a proteomic risk score to predict rapid lung function decline, identifying 32 proteins that predict respiratory disease and mortality. This score, derived from a 30-year cardiovascular health study, could lead to a preclinical blood test for early intervention in severe respiratory conditions like COPD.

Ignacio Durán discusses ESMO 2024 highlights in non-prostate genitourinary oncology, focusing on kidney and bladder cancer. Key findings include challenging the sequencing of checkpoint inhibitors in kidney cancer and new treatment options for non-clear cell carcinoma. In bladder cancer, studies like SunRISe-4, TOMBOLA, and NIAGARA could impact clinical practice, exploring alternatives to cisplatin-based neoadjuvant chemotherapy, ctDNA for patient selection in adjuvant therapy, and perioperative immunotherapy, respectively. Further research is needed to refine patient selection and optimize treatment strategies.

NYU Langone Health newsletter referenced AJMC.com's interview with Dr. Joshua K. Sabari on amivantamab for NSCLC. Becker’s GI & Endoscopy cited AJMC.com's article on updated colonoscopy guidelines. Pharmacy Times mentioned The Center for Biosimilars' report on FDA approval of ustekinumab-auub as a Stelara biosimilar.